When the effect of anti-EGFR mAbs was analyzed in patients with metastatic colorectal cancer with wild-type KRAS only, clinically relevant response rates increased to approximately 60% [49, 50]. The gene discussed is EGFR; the disease is metastatic colorectal cancer.